Zephyr AI Appoints Allen Hodge as Chief Commercial Officer
Zephyr AI, a high-growth healthcare technology company committed to radically reshaping traditional approaches to drug discovery precision medicine and predictive analytics has announced the appointment of Allen Hodge as Chief Commercial Officer. Hodge brings more than two decades of experience in building commercial organizations to this role. Prior to joining Zephyr AI, Hodge served as Senior Vice President and U.S. General Manager at BioCryst Pharmaceuticals, delivering a successful launch of Orladeyo for patients with hereditary angioedema.
Latest Aithority Insights: AiThority.com to Attend The Character of AI – A Technology Ethics Conference (Virtual)
“As we enter into our next phase of evolution and growth as a company, it is incredibly exciting to welcome Allen to the Zephyr AI team”
At Zephyr AI, Hodge provides senior leadership and strategic vision to support the company’s commercial efforts. Hodge oversees business development, strategic partnerships, and the commercialization of tools and products.
“The Zephyr AI team is poised to transform the way that the healthcare industry approaches drug discovery, development, and predictive analytics,” said Hodge, Chief Commercial Officer of Zephyr AI. “I’m extremely impressed by the team and the body of work that has already been accomplished. I am eager to lead the continued growth of the company and its efforts to propel AI-driven precision medicine and predictive analytics forward in the most disruptive way possible.”
Top Artificial Intelligence Insights: Could Instances of NLP Bias Derail AI?
Before BioCryst, Hodge worked as Vice President of U.S. Oncology Sales at Array Biopharma, which was acquired by Pfizer in 2019. Hodge led the sales organization that delivered the successful launch of Braftovi + Mektovi for patients with BRAF-mutant melanoma. Earlier in his career, Hodge served as a Regional Sales Director in hematology and oncology at Celgene, Inc, and as a Zone Director for Shire Pharmaceuticals (formerly ViroPharma, Inc) in ultra-rare disease. In addition, he has held various commercial roles over his more than 20+ year career to include sales, training, marketing, operations, and sales leadership.
“As we enter into our next phase of evolution and growth as a company, it is incredibly exciting to welcome Allen to the Zephyr AI team,” said David L. Morgan II, CEO of Zephyr AI. “The passion, energy, and expertise he brings to the role are unmatched, and his unique perspective will help ensure our success as we pursue our mission to build tools and products that will lead to the development of new therapies and novel indications of existing drugs to drastically improve patient outcomes while significantly lowering the total cost of care.”
AI ML in Marketing: AI and Big Data Analysis Used to Find Brands’ Emotional Connection
[To share your insights with us, please write to firstname.lastname@example.org]